New publication: Durable clinical responses in stage III–IV non-small-cell lung cancer patients treated with IDO peptide vaccine in a phase I study

Copenhagen, Denmark – September 28, 2018: IO Biotech has published a brief research report describing long term follow-up of phase I study in stage III-IV NSCLC in “Frontiers in Immunology”